Inventiva (NASDAQ:IVA) Shares Gap Down - Time to Sell?

Key Points

• Inventiva's stock price gapped down from $5.87 to $5.69 at market open, trading at $5.72 shortly after with a volume of 4,057 shares.
• Analysts maintain an overall positive outlook on Inventiva, with six analysts rating the stock as a Buy and a consensus price target of $15.57.
• Wealth Enhancement Advisory Services LLC has increased its stake in Inventiva by 54.5%, now holding 19.06% of the company's stock, valued at approximately $50,000.

Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Get Free Report)'s stock price gapped down before the market opened on Tuesday . The stock had previously closed at $5.87, but opened at $5.69. Inventiva shares last traded at $5.72, with a volume of 4,057 shares traded.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on IVA shares. Piper Sandler began coverage on Inventiva in a research report on Wednesday, August 27th. They issued an "overweight" rating and a $26.00 price objective for the company. Canaccord Genuity Group restated a "buy" rating and issued a $20.00 target price on shares of Inventiva in a research note on Tuesday. HC Wainwright started coverage on Inventiva in a report on Wednesday, September 3rd. They set a "buy" rating and a $20.00 target price on the stock. Finally, Guggenheim upped their price target on shares of Inventiva from $9.00 to $13.00 and gave the company a "buy" rating in a report on Tuesday, September 2nd. Six analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $15.57.

Inventiva Stock Down 0.9%

The firm's 50 day simple moving average is $4.67 and its two-hundred day simple moving average is $3.77.

Institutional Trading of Inventiva

A hedge fund recently raised its stake in Inventiva stock. Wealth Enhancement Advisory Services LLC increased its position in Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Free Report) by 54.5% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 16,558 shares of the company's stock after acquiring an additional 5,843 shares during the quarter. Wealth Enhancement Advisory Services LLC's holdings in Inventiva were worth $50,000 at the end of the most recent quarter. 19.06% of the stock is owned by institutional investors and hedge funds.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.